vs
MANNKIND CORP（MNKD）与Travere Therapeutics, Inc.（TVTX）财务数据对比。点击上方公司名可切换其他公司
Travere Therapeutics, Inc.的季度营收约是MANNKIND CORP的1.2倍（$129.7M vs $112.0M），Travere Therapeutics, Inc.同比增速更快（73.4% vs 45.8%），过去两年Travere Therapeutics, Inc.的营收复合增速更高（77.0% vs 30.0%）
曼凯德公司是一家生物制药企业，成立于1991年2月，总部位于美国康涅狄格州丹伯里，专注于糖尿病、肺动脉高压等疾病治疗药物的研发、生产及商业化推广，致力于为相关患者提供创新的治疗方案。
Travere Therapeutics是一家全球生物制药企业，专注于为罹患罕见、严重且危及生命疾病的患者开发和商业化创新疗法，核心覆盖罕见肾病、肝病及代谢疾病领域，业务覆盖北美、欧洲等主要市场。
MNKD vs TVTX — 直观对比
营收规模更大
TVTX
是对方的1.2倍
$112.0M
营收增速更快
TVTX
高出27.6%
45.8%
两年增速更快
TVTX
近两年复合增速
30.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.0M | $129.7M |
| 净利润 | $-15.9M | — |
| 毛利率 | 87.6% | 98.0% |
| 营业利润率 | -6.9% | -25.0% |
| 净利率 | -14.2% | — |
| 营收同比 | 45.8% | 73.4% |
| 净利润同比 | -314.9% | — |
| 每股收益（稀释后） | $-0.05 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MNKDTVTX
| Q4 25 | $112.0M | $129.7M | ||
| Q3 25 | $82.1M | $164.9M | ||
| Q2 25 | $76.5M | $114.4M | ||
| Q1 25 | $78.4M | $81.7M | ||
| Q4 24 | $76.8M | $74.8M | ||
| Q3 24 | $70.1M | $62.9M | ||
| Q2 24 | $72.4M | $54.1M | ||
| Q1 24 | $66.3M | $41.4M |
净利润MNKDTVTX
| Q4 25 | $-15.9M | — | ||
| Q3 25 | $8.0M | $25.7M | ||
| Q2 25 | $668.0K | $-12.8M | ||
| Q1 25 | $13.2M | $-41.2M | ||
| Q4 24 | $7.4M | — | ||
| Q3 24 | $11.6M | $-54.8M | ||
| Q2 24 | $-2.0M | $-70.4M | ||
| Q1 24 | $10.6M | $-136.1M |
毛利率MNKDTVTX
| Q4 25 | 87.6% | 98.0% | ||
| Q3 25 | 94.5% | 99.0% | ||
| Q2 25 | 94.0% | 98.7% | ||
| Q1 25 | 95.2% | 94.3% | ||
| Q4 24 | 93.7% | 96.6% | ||
| Q3 24 | 95.4% | 97.4% | ||
| Q2 24 | 92.3% | 96.2% | ||
| Q1 24 | 94.2% | 96.4% |
营业利润率MNKDTVTX
| Q4 25 | -6.9% | -25.0% | ||
| Q3 25 | 23.0% | 15.1% | ||
| Q2 25 | 6.9% | -11.1% | ||
| Q1 25 | 28.5% | -52.2% | ||
| Q4 24 | 34.5% | -81.2% | ||
| Q3 24 | 18.2% | -89.3% | ||
| Q2 24 | 22.9% | -125.1% | ||
| Q1 24 | 25.2% | -336.5% |
净利率MNKDTVTX
| Q4 25 | -14.2% | — | ||
| Q3 25 | 9.7% | 15.6% | ||
| Q2 25 | 0.9% | -11.1% | ||
| Q1 25 | 16.8% | -50.4% | ||
| Q4 24 | 9.7% | — | ||
| Q3 24 | 16.5% | -87.1% | ||
| Q2 24 | -2.8% | -130.1% | ||
| Q1 24 | 16.0% | -328.9% |
每股收益（稀释后）MNKDTVTX
| Q4 25 | $-0.05 | $0.04 | ||
| Q3 25 | $0.03 | $0.28 | ||
| Q2 25 | $0.00 | $-0.14 | ||
| Q1 25 | $0.04 | $-0.47 | ||
| Q4 24 | $0.03 | $-0.71 | ||
| Q3 24 | $0.04 | $-0.70 | ||
| Q2 24 | $-0.01 | $-0.91 | ||
| Q1 24 | $0.04 | $-1.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $171.3M | $93.0M |
| 总债务越低越好 | $354.6M | — |
| 股东权益账面价值 | $-51.0M | $114.8M |
| 总资产 | $792.2M | $605.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MNKDTVTX
| Q4 25 | $171.3M | $93.0M | ||
| Q3 25 | $260.0M | $110.9M | ||
| Q2 25 | $179.0M | $75.2M | ||
| Q1 25 | $181.5M | $61.9M | ||
| Q4 24 | $197.3M | $58.5M | ||
| Q3 24 | $251.6M | $36.4M | ||
| Q2 24 | $247.8M | $32.3M | ||
| Q1 24 | $300.7M | $43.3M |
总债务MNKDTVTX
| Q4 25 | $354.6M | — | ||
| Q3 25 | $109.7M | — | ||
| Q2 25 | $36.2M | — | ||
| Q1 25 | $36.1M | — | ||
| Q4 24 | $36.1M | — | ||
| Q3 24 | $227.9M | — | ||
| Q2 24 | $227.6M | — | ||
| Q1 24 | $264.1M | — |
股东权益MNKDTVTX
| Q4 25 | $-51.0M | $114.8M | ||
| Q3 25 | $-44.6M | $73.6M | ||
| Q2 25 | $-55.0M | $32.7M | ||
| Q1 25 | $-58.6M | $32.8M | ||
| Q4 24 | $-78.8M | $59.1M | ||
| Q3 24 | $-209.9M | $-30.5M | ||
| Q2 24 | $-225.8M | $15.1M | ||
| Q1 24 | $-230.0M | $74.1M |
总资产MNKDTVTX
| Q4 25 | $792.2M | $605.2M | ||
| Q3 25 | $494.6M | $538.6M | ||
| Q2 25 | $411.7M | $555.3M | ||
| Q1 25 | $410.1M | $548.8M | ||
| Q4 24 | $393.8M | $594.1M | ||
| Q3 24 | $464.2M | $504.4M | ||
| Q2 24 | $443.8M | $551.1M | ||
| Q1 24 | $480.9M | $663.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.0M | $60.7M |
| 自由现金流经营现金流 - 资本支出 | $-10.0M | — |
| 自由现金流率自由现金流/营收 | -8.9% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $13.7M | — |
8季度趋势，按日历期对齐
经营现金流MNKDTVTX
| Q4 25 | $-8.0M | $60.7M | ||
| Q3 25 | $23.6M | $14.3M | ||
| Q2 25 | $8.9M | $5.0M | ||
| Q1 25 | $-6.4M | $-42.2M | ||
| Q4 24 | $22.6M | $-35.7M | ||
| Q3 24 | $9.3M | $-42.5M | ||
| Q2 24 | $3.8M | $-40.2M | ||
| Q1 24 | $6.7M | $-119.0M |
自由现金流MNKDTVTX
| Q4 25 | $-10.0M | — | ||
| Q3 25 | $22.5M | $14.2M | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $-6.7M | — | ||
| Q4 24 | $19.7M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $861.0K | $-40.3M | ||
| Q1 24 | $4.3M | — |
自由现金流率MNKDTVTX
| Q4 25 | -8.9% | — | ||
| Q3 25 | 27.4% | 8.6% | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 25.7% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 1.2% | -74.5% | ||
| Q1 24 | 6.5% | — |
资本支出强度MNKDTVTX
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.4% | 0.1% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 2.0% | 0.0% | ||
| Q2 24 | 4.1% | 0.2% | ||
| Q1 24 | 3.6% | 0.0% |
现金转化率MNKDTVTX
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | 0.56× | ||
| Q2 25 | 13.40× | — | ||
| Q1 25 | -0.48× | — | ||
| Q4 24 | 3.05× | — | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.63× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MNKD
| Products | $50.4M | 45% |
| Royalty | $33.6M | 30% |
| Afrezza | $22.9M | 20% |
| V Go | $4.3M | 4% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
